Skip to Accessibility Menu Skip to Login Skip to Content Skip to Footer

FDA Recent Approval of Kanjinti (Biosimilar to Herceptin)

Editorial Team's avatar image

By Editorial Team

1 min read

Last month, the FDA approved Kanjinti, the 5th biosimilar to Herceptin. Kanjinti is approved for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer.1,2

By providing your email address, you are agreeing to our Privacy Policy and Terms of Use.

What is Kanjinti?

Kanjinti is a HER2 receptor antagonist that is a biosimilar to trastuzumab (Herceptin). Studies found that Kanjinti had no clinically meaningful differences to Herceptin. Kanjinti was developed as a collaboration between Amgen and Allergan but is not currently commercially available.2

What is a biosimilar?

Biosimilars are biological products that have been shown to be highly similar to an already-approved product. Biosimilars must have no clinically meaningful differences from their reference products with regard to effectiveness or safety and only small differences in clinically inactive components are allowable.3

Join the conversation

Please read our rules before commenting.